| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5925730 | FERRING | GnRH antagonists |
May, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10973870 | FERRING | Methods of treating prostate cancer with GnRH antagonist |
Feb, 2029
(4 years from now) | |
| US9579359 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Feb, 2029
(4 years from now) | |
| US10729739 | FERRING | Methods of treating prostate cancer with GnRH antagonist |
Feb, 2029
(4 years from now) | |
| US11766468 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(8 years from now) | |
| US9415085 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(8 years from now) | |
| US11826397 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(8 years from now) | |
| US10695398 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(8 years from now) | |
Firmagon is owned by Ferring.
Firmagon contains Degarelix Acetate.
Firmagon has a total of 8 drug patents out of which 1 drug patent has expired.
Expired drug patents of Firmagon are:
- US5925730
Firmagon was authorised for market use on 24 December, 2008.
Firmagon is available in powder;subcutaneous dosage forms.
Firmagon can be used as method of treating prostate cancer, gnrh antagonist indicated for treatment of patients with advanced prostate cancer, treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect.
Drug patent challenges can be filed against Firmagon from 24 December, 2012.
The generics of Firmagon are possible to be released after 27 April, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 24, 2013 |
Drugs and Companies using DEGARELIX ACETATE ingredient
NCE-1 date: 24 December, 2012
Market Authorisation Date: 24 December, 2008
Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect; Method of treating prostate cancer; Gnrh antagonist indicated for trea...
Dosage: POWDER;SUBCUTANEOUS
FIRMAGON family patents
